A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream

Inclusion Criteria: * Have provided written informed consent. * Generally healthy males or non-pregnant females, of any race or ethnicity, who are at least 18 years of age at the time of screening. * At Visit 1/Day 0, have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6 months duration involving scalp and body (trunk and/or limbs) that is amenable to topical treatment with a maximum of 100 g of trial medication per week. * Have a Physician's Global Assessment \[PGA\] of severity of at least moderate on the trunk, limbs and/or scalp, at Visit 1/Day 0. * Have a treatment area between 20% and 30% of the body surface area \[BSA\] on the trunk, limbs and/or scalp, excluding psoriatic lesions on the face, genitals, and intertriginous areas, at Visit 1/Day 0. Exclusion Criteria: * Current diagnosis of unstable forms of psoriasis * Other inflammatory skin disease in the treatment area * Pigmentation, extensive scarring, pigmented lesions or sunburn in the treatment areas * Planned exposure to natural or artificial sunlight * Phototherapy and ultraviolet B radiation within 4 weeks prior to Visit 1/Baseline and during the trial; * Current or past history of hypercalcemia, vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders; * Oral calcium supplements, vitamin D supplements, bisphosphonates or calcitonin within 4 weeks prior to Visit 1/Day 0 during the trial period. * Planned initiation of, or changes to concomitant medication that could affect calcium metabolism during the trial; * Planned initiation of, or changes to, concomitant estrogen therapy during the trial; * Strong systemic cytochrome P450 3A4 (CYP 3A4) inhibitors within 4 weeks prior to Vist 1/Day 0 and during the trial period; * Use of topical treatments, except for emollients and non-medicated shampoos, with a possible effect on psoriasis within 2 weeks prior to Visit 1/Day 0 and during the trial period; * Systemic treatment with biological therapies * Initiation of, or expected changes to, concomitant medication that may affect psoriasis during the trial period; * Depression and endocrine disorders known to affect cortisol levels or HPA axis integrity, non-nocturnal sleep patterns * Systemic medication that suppresses the immune system within 4 weeks prior to the Visit 1/Day 0 and during the trial period; * Clinical signs of skin infection with bacteria, viruses, or fungi; * Known human immunodeficiency virus \[HIV\] infection; * Known or suspected of hypersensitivity to any component of the test product or reference product; * Any chronic or acute medical condition that may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial;